Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's one this weekend from firstmicrocapreport.com that includes SMNG
Three Stocks You Absolutely Must Own Going Into June
What a week!
It started out with a Monday doubling of GEAR off a ridiculously short promotion that once again was handled carelessly. This is a stock that is begging to rocket off a properly executed, sustained promotion and if the financers could get their heads out of their butts, we could all make some big money. As I advised, I sold half of my position in the .04s and I am now riding essentially free stock which I will hold into the next obviously inevitable promotion. Congratulations to those who profited off my pre-promotion alert. Granted it took a little longer to get going than I anticipated, but if you kept accumulating into the .02s like I suggested, then you made out.
If you have sold your entire position or have not got into this deal yet, I think that you can accumulate GEAR in the low .02s, provided that you can hold it for a bit.
~
While, I like GEAR and all the other stocks I have on my watch list, mostly for future promotion value, I am now going to talk about the three stocks that I believe you will regret not owning as we go into June. In other words, if you do not already own them, you will be sorry. If you do own them, you may want to considering improving your position.
HAIR
Biostem US opened to rave reviews, following my Thursday afternoon alert. This company is worth an investment, although I do like taking a free stock position, i.e. selling half at a double or a third on a triple, in order to ride out the free stock. The balance is the stock you lock away in a vault and look at again in a year or two.
Yes I have been compensated for my profiling of Biostem US, but not because I am alerting it, but because I was retained to consult with the financers on the proper way to bring awareness to the company. It is indeed regretable that the public is getting raped with incessant repeat pushes that create nothing but loses for players of stocks like FROG, GCLL, MELY, OREO, HHII, ONTC, etc., etc. I have been approached to jump onto many of these bandwagons and make them my phony "picks" in exchange for cash payment, but I will not create a scenario for deliberate losses. So while I was retained for consultation purposes, in order to be sure that I am in full compliant with Section 17(b), I have disclosed my compensation. I also expect further compensation as the awareness campaign, which I am directing, continues.
Much to the credit of the financers of HAIR, they came to me looking for my advice as to the proper execution of an awareness campaign, without damaging shareholders. You see, these guys are real. Many of the insiders and founders of HAIR are also past and present insiders of CROCSTM and as we all know CROCSTM, with annual sales of a billion dollars, is no pump and dump. Still, they came looking to me for guidance, as the microcap market was a new area for them. And they listened.
I know that I teased the release of the symbol for a few weeks, but it was because I insisted that we hold back until the $5 million private placement was signed, sealed and delivered. And they listened.
It was I who recommended the symbol change from BOSM to HAIR, in order to bring instant recognition to the company's primary line of business, proprietary stem cell technology applied to hair re-growth. Even though the technology will eventually be applied to Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells, I believe that the new symbol is much more marketable. And they listened.
It was I who recommended the recent 3 for 1 split in shares, since there really wasn't much stock available and I wanted the stock to be accessible to those with smaller investment budgets. And they listened.
I worked with an incredibly professional group to bring HAIR to awareness readiness. And unlike other groups whose only goal is to pump away at an unsuspecting public, these guys are running a first class show, surrounding themselves with top doctors, financials advisors and yes, publicity advisors.
And look at the action in the stock. No bid smashing, even though there are plenty of bids that could have been whacked out there. No ridiculous gaps up. Just an orderly market with a steady increase in share price, although don't expect that there won't be down days, as profit taking is inevitable and healthy. Still nobody is in a hurry to dump stock.
All this is just the very beginning. To date, only my subscribers have received any documentation on HAIR. I'm not saying others haven't taken notice, like this newsletter, but the awareness is still in its infancy. As we speak, a full report is being prepared which will be distributed to my subscribers first and then followed by steady distribution to tens if not hundreds of thousands in the coming weeks. $2 million dollars has been earmarked for the awareness of HAIR's hair replacement procedure to the marketplace and awareness of the stock to the street. You, ladies and gentlemen, are truly on the ground floor.
It is hoped that the report will be distributed to my subscribers this weekend, but it may take a day or two longer to complete it. Either way, it will be eye opening.
SMNG
I have been on about this stock for quite a while now, and I am more convinced than ever that this thing is about to go on a significant promotion effort. Look at the evidence: the financials have recently been completed and the company is now fully compliant with all necessary filings. The mine licensing problems in Africa were recently resolved, and on Thursday SMNG announced it had achieved $5,000,000 Reserve Equity Financing in order to fund general Company operations and gold exploration work on that property.
One positive indicator is that the share price and trading volume have been steadily increasing since the financials were brought up to date and the dreaded "E" was dropped from the symbol.
But here's the smoking gun. Within the last two days, a few subscribers have pointed out the recent registration of the domain names, smngreport.com and smngnews.com. This is the trademark of a certain major promoter, who also has been significant in the ongoing promotion of ORYN. And that promoter has been running the websites orynreport.com and smngreport.com. Now I am not guaranteeing that this particular person will be involved SMNG's promotion, but it sure looks like somebody will be.
INHC
Now relegated to being my second favorite microcap stock (after HAIR) this one continues to act like a champ. The stock is maintaining its base even though some minor selling has pushed it down on a couple of occasions this week. Each time, the stock has rebounded and looks strong with a base of .10 - .11.
In addition to the recent filing of decent quarterly financials and the announcement of a $34 million backlog in orders to the US Department of Defense, the company filed an 8-K on Friday, in which it released details of the sale of $6 million in convertible debentures.
If you still haven't seen this, check out this link to the government list of contracts with INHC over the years.
Here's another interesting tidbit I found regarding an award the company received from the Army.
With 15 million shares reported issued and outstanding, the current market cap of INHC is about $1.5 million. I am still the only one talking about this company and before the rest of the world finds out, you should put some away. I expect that one day you will wake up and find this trading in the dollars not pennies.
So there you have it. You can try and catch the brief upswings on the garbage that the major emailers have been try to foist on you over and over again, or you could try and catch the first wave with stocks like HAIR, SMNG and INHC. In my opinion, these will all be strong performers from now and going into June.
~
DEAC filed its financials on Thursday and no one took notice of the fact that the company reported its first ever earnings. The company, which produces oil and carbon products from waste tires, has been sitting like a rock at 11 cents and I will be watching for strange trading activity in order to pinpoint a possible launch of a promotion. One thing is evident from the stock's limited trading. The paper is very tightly held. I believe that I am getting close to alerting this one in order to jump in front of a promotion.
~
GTCP continues to act like it is going to be subjected to a promotion in the near future, probably by Awesome Penny Stocks and its partners. Even though it is not the current pick, the stock has not tanked and cannot be bought unless you are will to go into the high .40s. I am trying to get into some more stock in the .20s and perhaps up to .30 on the off chance that some holder needs to cash out. You should read my pre-promotion alert on GTCP in order to understand the reasoning beind my belief that it is a future (probably the next) APS pick.
firstmicrocapreport.com is talking about INHC but they claim they are not being compensated. They have been on it for quite a while. Since it was 2 or 3 cents, I believe.
You gotta admit. It looks like LH hit the nail on the head with this one. Nothing but bids as far as the eye can see.
And on this from firstmicrocapreport.com
From The Founders Of CROCS
I Give You HAIR!
This is it! The Big Mamou! Steve Beck, Founder of CROCSTM and Scott Crutchfield, the current Vice President of World Wide Operations for CROCSTM and other CROCSTM insiders have teamed up with dozens of the greatest minds, including reknowned medical doctors, to enter into what will be the hottest industry of this decade: stem cell therapy. And this company is now generating revenues with their proprietary technology of using the patient's own stem cells to the number one cosmetic procedure undergone by men: hair replacement. That's right! They are not in the position of waiting for FDA approval! They are applying their technology now!
Welcome to Biostem US Corporation (HAIR). This company will be undoubtedly be the microcap play of 2012. And to prove it, the company just now announced $5,000,000 in equity financing at a share price above Wednesday's market close. You must read this press release. It is incredible news.
This company is about to undergo a massive publicity campaign in order to inform hair replacement candidates of the stem cell procedure available to them now, through Biostem. This will automatically bring attention to the investing public and with a stock awareness program that will employ only the most reputable newsletters, I expect this stock to skyrocket this year, next year and beyond that. Follicle-ly challenged, celebrity candidates are elbowing each other out of the way in order to be selected as the celebrity patient/spokesman for this procedure, and already $2 million has been earmarked for publicity with much more to come.
And hair replacement is just the beginning. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells.
Much of the float is locked down by Rule 144 selling restrictions, so there really isn't that much stock for sale. There is no additional stock available for dilution, so the float will stay intact for the foreseeable future. That is one of the reasons that the equity funder paid higher than market price for the private placement.
A full report is being produced as we speak and will be distributed to my subscribers first, this weekend. But I urge you, to look at this now and at least take a taste. I assure you that there is very little stock available at these levels.
If you thought that my pick of LUXR at 50 cents was a great pick, that was nothing. Mark my words, HAIR is the investment of the year.
sound like a huge industry...big press out
Biostem U.S., Corporation, (OTCQB: HAIR) (PINKSHEETS: HAIR) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announces a $5,000,000 financing agreement through private placement of stock.
CEO, Dwight Brunoehler, announced today that the company has signed an agreement with a funder to issue 20,000,000 shares of the company's common stock in exchange for $5,000,000 in cash or 25 cents ($.25) per share. No other considerations will be granted to the funder in exchange for the cash payment.
In announcing the funding agreement, Mr. Brunoehler commented, "We consider the eagerness of the funder to acquire Biostem shares at a price above the current market to be a tribute to our proven proprietary technology to enhance hair re-growth using human stem cells. Although we anticipated funding the company through the sale of a convertible debenture, the funder insisted on being able to acquire stock at a set price now, rather than risk having to convert at higher prices later. Although Rule 144 sale restrictions usually cause private placements of stock to be executed at a discount to the market, Biostem feels that its current share price is not truly reflective of the value of its proprietary technology; as well as the fact that the technology is already being employed, and the overall size of the hair replacement marketplace. It was for this reason that the company and the funder were able to come to an agreement to price the private placement above the current share price."
Another newsletter on GEAR
"All Aboard"
Today's Day Trade Pick Is: GEAR
GEAR is back in play today as we believe that yesterday's pullback from Monday's highs is representing a helluva an opportunity to get into a potentially powerful play. This one has already proved to be a great day trade several times since it started trading last year, but this time we think that GEAR is getting ready for some extended action. We will be watching GEAR into next week.
GEAR recently entered into the gold mining business and just announced a second signifcant roll back in its authorized number of shares.
Last year GEAR announced the execution of a joint venture agreement with Mission Holdings, LLC for placing into production the Silver Cord Mine in Arizona, a historically producing silver and gold mine with over 900 feet of existing tunnels! To that end, GEAR recently announced that it was partnering with Western Sierra Mining Corp (WSRA) in the opeeration of that mine.
Volume is always strong in this stock and it is well based at this price level.
It's time to into GEAR.
www.PennyStockDayTrades.com
great article calling for SMNG
First Microcap Report.com
OK, So GEAR Doubles Today
Now What?
It's been a nice day today for those of us holding GEAR. Long time subscribers know I have been calling for a promotion on this stock for a number of weeks and today we hit pay dirt. What do we do from here?
I believe that we are at the beginning of an aggressive campaign on GEAR, one that could see the stock redouble over the coming days. That having been said, I think that it is time to take a little off the table here. Perhaps half of our position. That is what I've done. Besides you need some money for the next stocks that are setting up just like GEAR.
While we were waiting for the financials to be brought up to date on GEAR, the stock took a beating. As recently as ten days ago, you could have bought in at .016. As soon as the financials were brought up to date, the stock began to inch slowly up, bringing us to the promotion which began today. There is another stock acting exactly the same way. It's an old favorite of mine and I am positive that it is also setting up for a promotion that could take place in the next few weeks. The stock is at a price at which it needs to be accumulated ahead of that inevitability.
And that stock is SMNG.
We have all been suffering together through the trials and tribulations of Strategic Mining Corp (SMNG). There were mine licensing issues in Africa which were resolved last month. There were deliquent financials which cause an "E" to be placed at the end of the symbol, a red flag for potential buyers. Now the deliquent financials have been filed and the "E" has been removed. Would a company that didn't have plans for something grand do this? I doubt it. There are quarterly financials which will be filed at the end of this month and then I think you will see the inching up out of the subpennies. And then something sweet will happen. The company has already announced that it is seeking financing for exploration of its African claims. I think that they have found it and that is why they are working so diligently to bring the financials up to date. I also think that a promotion will be used to appease those financers. Look at the history of these two companies and see if you don't agree that there are many procedural similarities between GEAR and SMNG. Even the number of shares issued are similar.
In short, you should own SMNG.
The other stock you should own is GEAR's partner in the development of mining claims in Arizona, Western Sierra Mining (WSRA). Both companies issued press today with respect to that project.
WSRA was the subject of a one day promotion last month, in what I believe was a first kick at the can. On that day, WSRA shares easily doubled and the stock has traded very little since. That indicates to me that most of the shares are being held in strong hands (insiders?) awaiting a much larger promotion, to be conducted perhaps after the GEAR promotion concludes. I would (and do) own WSRA in anticipation of such a promotion.
Congratulations to all of those who profited from my GEAR pre-promotion alert. I am now issuing pre-promotion alerts on SMNG and WSRA.
Disclosure: I own stock in GEAR and SMNG and WSRA.
Uncle Leslie called it! GEAR at 2 cents when I bought it.
well PPBL was promoted yesterday and there are already announcements that GEAR will be promoted Monday.
Looks like Uncle Leslie was right about this one. He said this would be promoted and he was right. Hopefully we will get a nice gap up on Monday.
firstmicrocapreport is the only one I've ever seen cover this stock. he picks some winners and some losers, but I think he has a major winner with this one. if it wasn't for Uncle Les, most of us would not have heard of this stock and if it goes to a buck like he says it will, all will be forgiven for the losses. I have been buying this since it was 4 cents and I keep adding. That buy at .0765 this morning was mine and I am bidding more at .08
These guys have been talking about this stock since it was 3 cents. They are calling for a buck this year and with no promotions.
Congrats to the longs but be careful. Good email this morning from firstmicrocapreport.com.
Awesome Penny Stocks and the Triple Fakeout
Yes, yes, I know. After deliberately fooling its fan club into buying first RARS, then PGSY and then ENRG, APS looks like it is coming out with GWBU, although so far this morning all I've seen is its sister sites promote it with emails. Not surprisingly, the other three stocks are all tanking this morning.
But, I still haven't seen an APS email on GWBU and I still don't see shill market maker Wilson-Davis (WDCO) on the bid side for GWBU. As I discussed in the Weekend Round-up, WDCO always ponies up phony big bids on APS promotions.
But let's assume that GWBU is the pick. For now. I don't think it will last long. They won't find quite the same kind of audience for a stock that started over a dollar, as they would for cheaper stocks. Of course they could tank the stock before APS does actually step in. Make sure you consider that possibility. There is a long way to fall on a $1.40 stock and the real pumping could start at a third of its current price.
Should you pack it in on GTCP? Nope! Anybody notice that that stock has not tanked? You know why? Because APS associates own all the stock.
I also wouldn't rule out PGSY. That stock is still a new deal and didn't really trade all that much in dollar volume on yesterday's fakeout. I am picking up a little taste of it this morning because I just have a gut feeling that something will happen here, with or without APS. Yesterday, HotOtc.com, often a collaborator with APS, came out on this one. HotOtc often comes out on a stock before the rest of the promoters, so I think somebody will follow up. Of course if APS did eventually promote this one, it would be a double psych.
I still think that the next pick, perhaps after GWBU (or PGSY) is likely to be Georgetown Corp (GTCP). And I'll repeat my resoning, below.
Until recently, Mackie Barch was running the show at GTCP. Barch still owns a ton of stock. According to a May 8, 2012 8K filing, Barch sold 74% of the company for $25,000. Yeah, right.
I promise you that there is some sort of a plan here for Barch get a few more dollars in his pocket. More likely, he is associated with APS itself. That would mean more than a few dollars.
Barch had to pretend give up control. You see, Barch is also the President and CEO of SNPK. And he has already publicly claimed that he has nothing to do with that promotion. Now he won't have to make the same claim with GTCP, because he won't speak for the company.
Need more? Mackie Barch also had/has a connection with another past APS promotion HDSI. At the time it was announced that Barch was to acquire the shell (previously named GMV Wireless), Barch ran a company called Healthcare Distribution Specialists, LLC. The GMV shell was renamed HDS International Corp and the symbol was changed to (HDSI). Then, without explanation, the Barch acquisition was called off (maybe). Still, with the Barch connection firmly established, APS ran the stock. HDSI was also the subject of a major promotion just this past April, although APS was not directly involved with that.
At 36 years old, Mackie Barch seems a little young to be the CEO of so many public companies, doesn't he? He certainly is not a poster child for loyalty to a company. Barch is just the sort of kid that people like to put in front of these kind of deals, as they will generally keep quiet and be lured in by the promised riches. In short, they do what they are told. I think that there is a strong chance that Barch works directly for/with APS.
With APS's favorite son firmly established, the other sign that GTCP is about to be an APS pick is that the stock didn't start trading until yesterday (Wednesday). I would think that it would be quite a coincidence that this thing starts trading just as the SNPK promotion expires.
There can be no question that APS will promote GTCP soon. Its fingerprints are all over this stock. The share price will probably drift for a while and will be worth accumulating on the anticipation of an inevitable promotion. I already own a little bit, but I would and am bidding this stock in the .20s.
I'll say it again. today's email from leslie makes sense
How I Know That RARS is
Not The Next APS Pick
I've been receiving a lot of kudos for pointing out the Awesome Penny Stocks fakeout on RARS and subscribers have been wondering how I knew that the stock was not the next APS pick. Well of course I won't know for sure, until they actually announce their next pick, but I took an educated guess by looking at their recent promotions for a clue.
Here's what I found: looking at APS's last several picks SNPK, NSRS, AMWI, MILV, POTG and HDSI, none had filed financials since the reverse takeover that created these new entities and prior to the APS promotion. In other words, it was impossible to discern what the assets of the company actually were, because all financials that had been filed were actually reflective of the shell from its previous life. Furthermore, the APS promotion always ends prior to the filing of new financials, which has always shown that the company is worthless and/or way over market capitalized, thanks to APS.
Looking at RARS, we have already seen a couple of financials filed on behalf of the company by President Manfred Ruf, and their can be no doubt that the company is penniless and has no intrinsic assets. Their is no way that APS could justify an extended promotion of RARS based on air, and no way to concoct a story while maintaining some sort of sense of credibility with those who still have not figured out that APS is in the business of selling the stocks of worthless companies. A promotion was not going to be successful beyond the initial frenzy created by the speculation of APS participation. That frenzy is easily created without a formal APS announcement. APS is certainly not going to be able to pump something that hadn't already been declared, without drawing the attention of the regulators and without creating doubt of their own credibility.
With the exception of SNPK, which has not yet filed financials since the promotion concluded, the financials of the other aforementioned APS promotions prove out the theory that APS always ends the promo just prior to the company needing to show the world that it is actually worthless. All of these companies had at one time boasted market caps of $100 - $750 million, thanks to APS, and yet in their latest financials, they identify assets which are poor in cash and mostly made up of arbitrarily valued properties of the company.
NSRS lists assets of $819K, $755K of which are mineral properties. AMWI lists assets of $596K, $550k of which they call intangible (i.e. invisible). MILV lists assets of $1.1 million, $988K of which are in formulas. POTG, which less than a year ago had a market cap of over $700 million, lists $635 in cash as its only asset. HDSI has $327K in cash as its only listed asset. And almost all of these companies have listed liabilities that more than cancel out any asset value that they have.
As you can see, none of these companies could have ever justified even 1% of their once heady market caps and that's why APS has to promote these companies before the initial financials come out, at which time they are proved to be essentially worthless.
SNPK, has offered window dressing to their prospective asset value by putting Clotamin on the shelves of famous retailers. What APS never talked about, but was evident in 8K filings, was that SNPK paid these retailers hundreds of thousands of dollars to put Clotamin on their shelves. Notice how of all the press releases issued trumpeting the availability of Clotamin, not one talks about the sale of a single bottle. For all we know, every single bottle of Clotamin shelved is still on that shelf. I suspect that the financials which are imminently due, will bear out the pattern of assets which pale the ridiculous market cap that this company once carried, and that sales figures will be embarrassing considering the big names retailers that Clotamin is supposedly found at.
And this is where we come to GTCP, which I have already predicted is the next APS promotion and if not the next one, certainly the one after that. It meets all the criteria of a major APS promotion in that financials have yet to be filed in its current incarnation, and it has the past APS promotion connection in Mackie Barch, who was/is involved with SNPK and HDSI. I think that APS connections probably own most of the GTCP stock. If you haven't already read my prognostication of GTCP, you may retrieve it by clicking here.
logical email from firstmicrocapreport
How I Know That RARS is
Not The Next APS Pick
I've been receiving a lot of kudos for pointing out the Awesome Penny Stocks fakeout on RARS and subscribers have been wondering how I knew that the stock was not the next APS pick. Well of course I won't know for sure, until they actually announce their next pick, but I took an educated guess by looking at their recent promotions for a clue.
Here's what I found: looking at APS's last several picks SNPK, NSRS, AMWI, MILV, POTG and HDSI, none had filed financials since the reverse takeover that created these new entities and prior to the APS promotion. In other words, it was impossible to discern what the assets of the company actually were, because all financials that had been filed were actually reflective of the shell from its previous life. Furthermore, the APS promotion always ends prior to the filing of new financials, which has always shown that the company is worthless and/or way over market capitalized, thanks to APS.
Looking at RARS, we have already seen a couple of financials filed on behalf of the company by President Manfred Ruf, and their can be no doubt that the company is penniless and has no intrinsic assets. Their is no way that APS could justify an extended promotion of RARS based on air, and no way to concoct a story while maintaining some sort of sense of credibility with those who still have not figured out that APS is in the business of selling the stocks of worthless companies. A promotion was not going to be successful beyond the initial frenzy created by the speculation of APS participation. That frenzy is easily created without a formal APS announcement. APS is certainly not going to be able to pump something that hadn't already been declared, without drawing the attention of the regulators and without creating doubt of their own credibility.
With the exception of SNPK, which has not yet filed financials since the promotion concluded, the financials of the other aforementioned APS promotions prove out the theory that APS always ends the promo just prior to the company needing to show the world that it is actually worthless. All of these companies had at one time boasted market caps of $100 - $750 million, thanks to APS, and yet in their latest financials, they identify assets which are poor in cash and mostly made up of arbitrarily valued properties of the company.
NSRS lists assets of $819K, $755K of which are mineral properties. AMWI lists assets of $596K, $550k of which they call intangible (i.e. invisible). MILV lists assets of $1.1 million, $988K of which are in formulas. POTG, which less than a year ago had a market cap of over $700 million, lists $635 in cash as its only asset. HDSI has $327K in cash as its only listed asset. And almost all of these companies have listed liabilities that more than cancel out any asset value that they have.
As you can see, none of these companies could have ever justified even 1% of their once heady market caps and that's why APS has to promote these companies before the initial financials come out, at which time they are proved to be essentially worthless.
SNPK, has offered window dressing to their prospective asset value by putting Clotamin on the shelves of famous retailers. What APS never talked about, but was evident in 8K filings, was that SNPK paid these retailers hundreds of thousands of dollars to put Clotamin on their shelves. Notice how of all the press releases issued trumpeting the availability of Clotamin, not one talks about the sale of a single bottle. For all we know, every single bottle of Clotamin shelved is still on that shelf. I suspect that the financials which are imminently due, will bear out the pattern of assets which pale the ridiculous market cap that this company once carried, and that sales figures will be embarrassing considering the big names retailers that Clotamin is supposedly found at.
And this is where we come to GTCP, which I have already predicted is the next APS promotion and if not the next one, certainly the one after that. It meets all the criteria of a major APS promotion in that financials have yet to be filed in its current incarnation, and it has the past APS promotion connection in Mackie Barch, who was/is involved with SNPK and HDSI. I think that APS connections probably own most of the GTCP stock. If you haven't already read my prognostication of GTCP, you may retrieve it by clicking here.
Unless the "buyers" were also the "sellers"
Wait a second. Isn't that what happens with every pump? It gets pumped, the promoters or insiders sell into it and then it crashes. Sometimes we make money, sometimes we don't. What is so different here?
You gotta hand it to these guys. They called the landslide vote on Saturday.
May 5, 2012
It's widely known that Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is in a battle with Vivus, Inc. (NASDAQ: VVUS) and Orexigen Therapeutics, Inc. (NASDAQ:OREX) to be first on the market with the first new weight loss drug in over a decade. It is just as widely known that the FDA is under somewhat self-inflicted pressure to approve such a drug, especially since FDA Commissioner Margaret Hamburg’s speech, last month, in which she affirmed that obesity is a disease rather than just a voluntary condition and the public is insisting on treatment:
"Patients are urgently waiting for new therapies—and often not getting them. And we are not adequately addressing burgeoning public health needs. Disease conditions such as obesity and Alzheimer’s, are taking a growing toll, profoundly affecting American families, and measurably adding to our health care costs and our national debt."
Of the three drugs under consideration for approval, Arena’s Lorcaserin is the only novel approach, whereas Vivus’ Qnexa and Orexigen’s Contrave are combinations of other compounds (drugs). This would seem to give an advantage to Arena as the U.S. Senate Committee on Appropriations, within its AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES APPROPRIATIONS BILL, 2012, ordered a report from the FDA on the steps that will be taken to support novel treatments for obesity.
“The Committee is concerned with the absence of novel medicines to treat obesity, the second leading cause of preventable deaths in the United States and a disease linked to cancer, high blood pressure, heart disease, diabetes, and stroke. With only diet, exercise, and gastric surgery as options, the lack of obesity medications is a significant unmet medical need. The Committee directs FDA to report by March 30, 2012 on the steps it will take to support the development of new treatments for obesity, including the use of its Risk Evaluation and Mitigation Strategy and other post-marketing authorities, to mitigate risk and ensure rigorous post-market scrutiny while increasing access to novel medications.”
Lorcaserin, received a thumbs down from a previous FDA Advisory Committee, that in 2010 expressed four concerns that were required to be addressed by Arena, before an approval for the drug, by the committee, could be considered. The committee’s rejection was confirmed by the FDA’s Complete Response Letter, which followed.
Within its rejection, the FDA cited carcinogenicity issues, which included diagnostic uncertainty in the classification of masses in female rats (strange tumors which were found in mammary tissue in animal studies), unresolved exposure-response relationships for Lorcaserin-emergent mammary adenocarcinoma (ambiguity over the mechanism of carcinogenicity), and an unidentified mode of action and unclear safety margin for Lorcaserin-emergent brain astrocytoma. The complete response letter also stated specifically that the FDA wanted to see a much more detailed explanation of the tumors that arose in the rats, and a better way of understanding Lorcaserin’s distribution to the central nervous system to better evaluate the risk of astrocytoma exposure margins in humans.
In response to the rejection, Arena seems to have diligently worked to alleviate the FDA’s concerns. Arena accumulated more data to prove that Lorcaserin’s benefits outweigh the risks in a new study and a month after the initial FDA rejection, the company released its BLOOM-DM trial results, which showed that after one year of treatment, 37.5% of patients taking Lorcaserin lost at least 5% of their body weight, which meets the FDA criteria for approval of a weight-loss drug. Even more encouraging was that over 16% of Lorcaserin patients lost over 10% of their body weight.
With respect to the concern of mammary masses in female rats, in August of 2011, Arena announced results from a Pathology Working Group, consisting of five pathologists contracted by Arena, with the approval of the FDA. The group was convened to re-adjudicate the female rat mammary tumor diagnoses from the two-year rat carcinogenicity study of Lorcaserin in question. Following a review of the relevant tissue samples, the group reported that benign tumors were more prevalent in the samples than malignant tumors, and that there was no significant cancer risk to humans, as a result of taking Lorcaserin.
The Pathology Working Group’s findings may also have resolved the concern the FDA had with unresolved exposure-response relationships for Lorcaserin-emergent mammary adenocarcinoma, since it might now be determined that mammary cancer is no longer a concern for those taking Lorcaserin.
Finally, and with respect to the FDA’s need for clarity of a safety margin for Lorcaserin-emergent brain astrocytoma, Arena announced on August 2, 2011, that a subsequent clinical study that measured Lorcaserin concentrations in human cerebrospinal fluid (CSF) and plasma, seemed to show that humans concentrate Lorcaserin within the brain at very low levels. The results of this study, could alleviate the FDA’s concerns that the drug concentrated in the brain of male rats at higher levels.
Heavily weighted in Arena’s favor, is that the FDA didn’t reference a possibility of heart-valve damage as a result of Lorcaserin use, a concern they expressed in the Complete Response Letters issued regarding Vivus’ Qnexa and Orexigene’s Contrave. Arena has conducted extensive heart safety testing, which presumably showed that there was no increase in heart valve risk with Lorcaserin.
We think that the FDA Advisory Committee is going to take its lead from the FDA Commissioner and the U.S. Senate Committee on Appropriations and recommend approval of Lorcaserin, in a landslide vote result similar to that of Vivus’ Qnexa 20-2 result. Ultimately, Lorcaserin may not receive final FDA approval for reasons that we don’t understand at this time, but we think that it is likely that the panel will take the burden of making that decision off its own shoulders.
http://www.legitimateinvestor.com/p/arna.html
RARS according to firstmicrocapreport.com
GTCP, ARNA and INHC on Watch
RARS Is Not
Yes, it sure looks like I nailed it when I suggested that RARS might not be the next Awesome Penny Stock pick. It now looks more and more like I was correct, especially after the tank job the stock pulled at the end of the day. I suggested that APS was pulling a fast one, wanting you to believe that RARS was the pick, much like they did with AWSR, they were just looking for a spurt of volume in the stock. This play was done very well, as about $30 million of stock was dumped over two days and with more probably to come today. Heck, they even used their favorite psych-you-out market maker Wilson-Davis (WDCO) to pony up phoney large bids.
For those of you who missed it, at lunch time yesterday, I came out with what I think is going to be the new APS pick. I'll repeat my reasoning here.
I think that the pick is likely to be Georgetown Corp (GTCP). And for one significant reason: Mackie Barch.
Until recently, Mackie Barch was running the show at GTCP. Barch still owns a ton of stock. According to a May 8, 2012 8K filing, Barch sold 74% of the company for $25,000. Yeah, right.
I promise you that there is some sort of a plan here for Barch get a few more dollars in his pocket. More likely, he is associated with APS itself. That would mean more than a few dollars.
Barch had to pretend give up control. You see, Barch is also the President and CEO of SNPK. And he has already publicly claimed that he has nothing to do with that promotion. Now he won't have to make the same claim with GTCP, because he won't speak for the company.
Need more? Mackie Barch also had/has a connection with another past APS promotion HDSI. At the time it was announced that Barch was to acquire the shell (previously named GMV Wireless), Barch ran a company called Healthcare Distribution Specialists, LLC. The GMV shell was renamed HDS International Corp and the symbol was changed to (HDSI). Then, without explanation, the Barch acquisition was called off (maybe). Still, with the Barch connection firmly established, APS ran the stock. HDSI was also the subject of a major promotion just this past April, although APS was not directly involved with that.
At 36 years old, Mackie Barch seems a little young to be the CEO of so many public companies, doesn't he? He certainly is not a poster child for loyalty to a company. Barch is just the sort of kid that people like to put in front of these kind of deals, as they will generally keep quite and be lured in by the promised riches. In short, they do what they are told. I think that there is a strong chance that Barch works directly for/with APS.
With APS's favorite son firmly established, the other sign that GTCP is about to be an APS pick is that the stock didn't start trading until yesterday (Wednesday). I would think that it would be quite a coincidence that this thing starts trading just as the SNPK promotion expires.
At any rate, whether RARS is the next APS pick or not, there can be no question that APS will promote GTCP soon. It's fingerprints are all over this stock. I would say that there is a 75% liklihood that GTCP is next, but 100% that it is coming. If GTCP is the next pick, then we all know what will happen. If not, the share price will probably drift for a while and will be worth accumulating on the anticipation of an inevitable promotion.
The following is important!
My favorite hold-on-tight-until-it-moves stock, INHC, has been gaining in share price and volume over the last couple of days, ahead of its May 21st quarterlies, for which the company has already announced that it expects to beat revenue expectations by 5%; and; since it issued a press release announcing a $34 million backlog in orders to the US Department of Defense. I will ask you again, how many 6 cent companies have you heard of that not just have a $34 million backlog, but have those kind of orders at all? We are talking about a company that reported less than $5 million in revenues all of last year!
The company also announced that it will release its quarterly financials on May 21st. They expect revenues will exceed projections by 5%.
In case you haven't seen this in the past, check out this link to the government list of contracts with INHC over the years.
With 15 million shares reported issued and outstanding, the current market cap of INHC is $1 million. Nobody knows about this company except my readers and before the rest of the world finds out, you should put some away. I expect that one day you will wake up and find this trading in the dollars not pennies.
Back in March, I told you to watch Arena Pharmaceuticals (ARNA) for a big move ahead of the FDA Panel meeting on May 10, at which members would vote to recommend approval of the company's weight-loss drug. Sure enough, the stock doubled ahead of the meeting and yesterday the committee voted to recommend approval. The stock looks to at least redouble again today. Congratulations to those who joined me in this play.
He has had some losers. But I made money on a few too. Funny how he took his name off the website. The key is to do quick trades on his picks. Of course that's the key with all of these pumps.
Another email where these guys are saying RARS is not the pick
RARS The Next Awesome Penny Stock Promotion? Don't Be So Sure!
At about 2:00pm yesterday, when everybody was buzzing that RARS was the next Awesome Penny Stock pick, my response was "don't be so sure". In fact, I posted it on my splash page and if you don't believe me, there are several posts on Investors Hub that confirm it, like this one.
Sure enough, out came APS and its sisters last night with a reiteration on SNPK, which will likely see a big, albeit short, bounce today.
Remember APS's fakeout on AWSR? I think that they are doing it again. In fact, they are doing it again, even if RARS turns out to be their next promotion. In that case, it would be a double fakeout: making you think it was the pick, then maybe not, but yes it is.
But I think that APS wanted you to believe that it was RARS, just to give them a short term boost, much like they did with AWSR. Would APS have allowed so many promoters to beat them to the punch, if RARS really was their next pick? I don't think so. And the SNPK reiteration seems to support my hypothesis. At any rate, RARS is lible to take a major dump today and APS will peeve off a lot of people...again.
What is the next major APS promotion? I think I know and I will give you the symbol at some point today, even though the stock is trading at levels that seem a little high to me. Still, I don't want to get beat to the punch and you never know when APS will declare. So stay tuned to your Inbox.
Stocks On Watch: SAPX, TWDL, HPCS, PSPF, WGAS, PPBL, CURX, SMNGE, BISU, OVIT, PNAM, DEAC, INHC, GEAR, HEMP, FORC, WLOL
Another good article Arena Shareholders Hold Their Breath
"Whereas just a few days ago, many were predicting the demise of Lorcaserin and with it Arena's hope for survival, now even one of the staunchest of Arena bears, Adam Feuerstein of TheStreet.com, has changed his tune, giving Lorcaserin/Arena a 60% chance of receiving the thumbs up from the FDA Advisory Committee, up from his previous 30-40% morning line odds." www.legitimateinvestor.com
Solid thinking...these guys say don't be so sure
Is RARS the next major
Awesome Penny Stocks promotion?
Don't be so sure!
Remember the AWSR fakeout?
I think this is the same thing!
I am about to reveal what the next major APS promotion is
to my subscribers and tell them why!
The next Awesome Penny Stocks promotion IS NOT RARS!
according to
www.firstmicrocapreport.com
You'd have to ask those guys. I have no idea.
5 bucks if FDA Committee recommends. 9 - 12 bucks on FDA approval.
Arena's Lorcaserin is Likely To Be Given Thumbs Up By FDA Advisory Committee
It's widely known that Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is in a battle with Vivus, Inc. (NASDAQ: VVUS) and Orexigen Therapeutics, Inc. (NASDAQ:OREX) to be first on the market with the first new weight loss drug in over a decade. It is just as widely known that the FDA is under somewhat self-inflicted pressure to approve such a drug, especially since FDA Commissioner Margaret Hamburg’s speech, last month, in which she affirmed that obesity is a disease rather than just a voluntary condition and the public is insisting on treatment:
"Patients are urgently waiting for new therapies—and often not getting them. And we are not adequately addressing burgeoning public health needs. Disease conditions such as obesity and Alzheimer’s, are taking a growing toll, profoundly affecting American families, and measurably adding to our health care costs and our national debt."
Of the three drugs under consideration for approval, Arena’s Locaserin is the only novel approach, whereas Vivus’ Qnexa and Orexigen’s Contrave are combinations of other compounds (drugs). This would seem to give an advantage to Arena as the U.S. Senate Committee on Appropriations, within its AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION, AND RELATED AGENCIES APPROPRIATIONS BILL, 2012, ordered a report from the FDA on the steps that will be taken to support novel treatments for obesity.
“The Committee is concerned with the absence of novel medicines to treat obesity, the second leading cause of preventable deaths in the United States and a disease linked to cancer, high blood pressure, heart disease, diabetes, and stroke. With only diet, exercise, and gastric surgery as options, the lack of obesity medications is a significant unmet medical need. The Committee directs FDA to report by March 30, 2012 on the steps it will take to support the development of new treatments for obesity, including the use of its Risk Evaluation and Mitigation Strategy and other post-marketing authorities, to mitigate risk and ensure rigorous post-market scrutiny while increasing access to novel medications.”
Locaserin, received a thumbs down from a previous FDA Advisory Committee, that in 2010 expressed four concerns that were required to be addressed by Arena, before an approval for the drug, by the committee, could be considered. The committee’s rejection was confirmed by the FDA’s Complete Response Letter, which followed.
Within its rejection, the FDA cited carcinogenicity issues, which included diagnostic uncertainty in the classification of masses in female rats (strange tumors which were found in mammary tissue in animal studies), unresolved exposure-response relationships for Lorcaserin-emergent mammary adenocarcinoma (ambiguity over the mechanism of carcinogenicity), and an unidentified mode of action and unclear safety margin for Lorcaserin-emergent brain astrocytoma. The complete response letter also stated specifically that the FDA wanted to see a much more detailed explanation of the tumors that arose in the rats, and a better way of understanding Lorcaserin’s distribution to the central nervous system to better evaluate the risk of astrocytoma exposure margins in humans.
In response to the rejection, Arena seems to have diligently worked to alleviate the FDA’s concerns. Arena accumulated more data to prove that Lorcaserin’s benefits outweigh the risks in a new study and a month after the initial FDA rejection, the company released its BLOOM-DM trial results, which showed that after one year of treatment, 37.5% of patients taking Lorcaserin lost at least 5% of their body weight, which meets the FDA criteria for approval of a weight-loss drug. Even more encouraging was that over 16% of Lorcaserin patients lost over 10% of their body weight.
With respect to the concern of mammary masses in female rats, in August of 2011, Arena announced results from a Pathology Working Group, consisting of five pathologists contracted by Arena, with the approval of the FDA. The group was convened to re-adjudicate the female rat mammary tumor diagnoses from the two-year rat carcinogenicity study of Lorcaserin in question. Following a review of the relevant tissue samples, the group reported that benign tumors were more prevalent in the samples than malignant tumors, and that there was no significant cancer risk to humans, as a result of taking Locaserin.
The Pathology Working Group’s findings may also have resolved the concern the FDA had with unresolved exposure-response relationships for Lorcaserin-emergent mammary adenocarcinoma, since it might now be determined that mammary cancer is no longer a concern for those taking Locaserin.
Finally, and with respect to the FDA’s need for clarity of a safety margin for Lorcaserin-emergent brain astrocytoma, Arena announced on August 2, 2011, that a subsequent clinical study that measured Lorcaserin concentrations in human cerebrospinal fluid (CSF) and plasma, seemed to show that humans concentrate Locaserin within the brain at very low levels. The results of this study, could alleviate the FDA’s concerns that the drug concentrated in the brain of male rats at higher levels.
Heavily weighted in Arena’s favor, is that the FDA didn’t reference a possibility of heart-valve damage as a result of Locaserin use, a concern they expressed in the Complete Response Letters issued regarding Vivus’ Qnexa and Orexigene’s Contrave. Arena has conducted extensive heart safety testing, which presumably showed that there was no increase in heart valve risk with Lorcaserin.
We think that the FDA Advisory Committee is going to take its lead from the FDA Commissioner and the U.S. Senate Committee on Appropriations and recommend approval of Locaserin, in a landslide vote result similar to that of Vivus’ Qnexa 20-2 result. Ultimately, Locaserin may not receive final FDA approval for reasons that we don’t understand at this time, but we think that it is likely that the panel will take the burden of making that decision off its own shoulders.
http://www.legitimateinvestor.com/
schlock is schlock. that I knew that this would go nowhere and you didn't, speaks volumes.
told you so
Here's another promo
"All Aboard"
Today's Day Trade Pick Is: MDRM
Modern Mobility Aids, Inc. is a Toronto based life sciences and healthcare industry company with a mandate to acquire and joint-venture with companies within the Biopharma sector, targeting both innovative research and development as well as scalable manufacturing capacity in three niche market segments: CRAM (Contract Research and Manufacturing for Life Sciences Companies), HEALTHCARE INNOVATION (Novel Drug and Device Delivery Format Packaging) and BIOPHARMA PARTNERSHIPS (Strategic Development and Production Alliances).
After Friday's close, the company announced an Agreement with ACGT Corporation to combine its resources and expertise with MDRM's soon-to-be wholly owned subsidiary, Lumigene Technologies, Inc. (Lumigene) to develop and commercialize molecular diagnostic products.
ACGT Corporation is considered to be one of the prominent Canadian providers of DNA services and has experience in developing and commercializing DNA based testing equipment.
Lumigene is engaged in developing molecular diagnostic products for the rapid and accurate detection of a number of specific pathogens and infectious diseases. In a recent press release, Modern Mobility Aids announced the definitive agreement to acquire Lumigene Technologies, Inc. This pending acquisition by the Company could address the ever-increasing demand for less time-consuming and more cost-effective methods of DNA testing and diagnosis of infectious diseases at point of care. Current testing methods typically require several days' work by highly trained technicians in an off-site laboratory.
We think that Friday's news makes MDRM Monday's two cent wonder play.
www.PennyStockDayTrades.com
worthless P and D
guaranteed this goes straight south
A pump on PFNI just started. Psychic Friends Network. Didn't Dionne Warwick push that schlock for a while on TV? WHo the heck would buy this crap?
Here you go: From firstmicrocapreport. com
I Know Which Stock Awesome Penny Stocks Is Promoting Next
Well it appears that the SNPK promo is over, as the stock has fallen into the toilet and there doesn't seem to be any forthcoming emails this morning. That's about right, as the game is about two months old now, and that is long as APS goes with any promo. Look for a new promo to begin within the next few trading sessions, I would guess next Wednesday or Thursday.
In the past, I've nominated stocks that I've speculated could be a future APS promotion. This time, I'm not going to do that, because I believe that I know which stock APS is going to promote next. I've been watching this stock for 4 months now, even though it doesn't trade yet, but the pattern is eerily similar to past APS promotions. Even the pre-promotion dead silence has become a trademaker of recent APS promotions, with the exception of the recent non-promotion promotion of AWSR. What's even more telling is that the market makers are talking about this stock, like it's fait accompli.
I'm not going to tell you which stock I am referring to, because, as I said, it is not trading, and there are no MMs on the bid or ask. Also, I don't want to start a speculative conversation on the message boards and scare away the promotion. I will give you the symbol, once the stock does start trading and if the ducks continue to be in a row. That may be a day or two before the promotion starts or only a matter of hours or minutes ahead of time. So watch your Inbox.
Well the TWDL IR letter that I talked about a couple of days ago, seems to be genuine, as it now has been posted onto the TWDL website. I would assume that we are ever closer to the annual promotion campaign on ths one and as you can see by the trading of the last couple of weeks, there is really not a lot of stock for sale at this level. I would continue to accumulate in the .02s, especially if you don't already own some.
BISU had a nice 20% move yesterday, on news that it has "entered a new era" by entering into the market for supplements geared towards those with Type II diabetes. Now that the company is communicating again, I believe that we can begin looking at it with an eye towards a coming promotion. The company has promised production news soon, and I believe that it will be at that point when the promotion efforts will commence.
tons of resistance here
And another one. They say unpaid.
First Microcap Report.com
Your Morning Coffee
Watch SAPX For The Next Few Days
While I am not officially alerting SAPX, I have to admit that I've been watching it for a few days, ever since they announced that they would not be reverse splitting the stock (yet) in order to maintain their NASDAQ listing. Now yes, I know that they have until September 20 to come into the share price compliance and the likelihood is that there will be a reverse split, but who makes an announcement of a non-event? It sure seems like they are trying to drum up interest in their stock, doesn't it?
If SAPX ever does announce the rumored casting of Bruce Willis into the lead of "Neuromancer", a film based on the popular cyberpunk novel, that could also send the stock into a tizzy. At any rate, I do believe that they will try hard to get interest in the shares and since there has never been a reluctance to use the heavy-handed promoters in the past, I would be shocked if they didn't remploy them. The only question is, will they be able to get the share price up? I am going to take a small gamble that they can get to 20 cents in the short term.
TGTX pulled a fast one with a reverse split this week and I for one, am not happy about it. This was strictly a ploy to get rid of the rest of the old shareholders as the company had already executed a reverse split last July, so there was no reason for another one, except to appease the new financers. The good news is that the share price has not suffered, at least not yet, as a result of the reverse. The bad news is that I am no longer interested in following it. So I will slowly be divesting myself of my stock, without whacking out the few bids out there. If you wish to do the same, keep in mind that there is no hurry to do so. There is now only 5 million shares out there, so there is no need to whack out everything down to a buck. Sit on the offer, much like I teach you to sit on the bid. Incidentally, for the next 4 weeks, the symbol will be TGTXD, due to the split.
You're only a short time away from finding out what the founders of CROCs (CROX), the makers of those ridiculously comfortable shoes, are up to next and I tell you, you won't believe it. And you will hear it from me first.
Stocks On Watch: SAPX, LUXR, TWDL, HPSC, PSPF, WGAS, PPBL, CURX, SMNGE, BISU, OVIT, PNAM, DEAC, INHC, GEAR, HEMP, FORC, WLOL
Here's another one. They say they were paid $5,000
"All Aboard"
Today's Day Trade Pick Is: SAPX
A lot has been going on at Seven Arts Entertainment lately, including deals for television releases of several of their movie productions and the about to be filmed cyberspace thriller, "Neuromancer", based on the popular novel and reportedly to star Bruce Willis.
SAPX recently announced that there are no plans to reverse split their stock even though the share price has bottomed out at the 10 - 11 cent range. The company feels that it can save its NASDAQ listing purely on interest in the stock. That means that the share price will need to climb to a buck by September! Will they do it? Who knows, but we're betting that there will be a bounce, a big bounce, off these lows, as they try to get to a dollar.
Better buy your tickets to SAPX!
www.PennyStockDayTrades.com
This is interesting
First Microcap Report.com
What Are The Founders of Crocs, Inc (CROX) Up To Next?
Everybody knows that Crocs are probably the greatest shoe story of the last 6 years. The company generates revenues of over $1 billion per year and net income of over $100 million per year. While the company's Proprietary Closed Cell Resin (PCCR) is what makes Crocs shoes soft and so comfortable, the company is expanding into other product lines and finding new applications for PCCR.
But enough about Crocs.
Now there's the next thing. No, I'm not talking about a shoe better than Crocs. I'm talking about the next project the founders of Crocs are into and would you believe that it is in the biotech market? These guys have taken a complete left turn from the shoe business and into one of the most intensely researched subjects in the medical field today. And they have taken that research and applied it to one of the biggest cosmetic problems that concerns men and women today. And as you would expect anybody with the success rate of Crocs, this new project is already turning heads.
Now the company which has applied this medical breakthrough into the cosmetic enhancement field, has gone public. And you have never heard of it. Not yet. And you won't today. I want you to get ready. Here's why.
The company has come to me to introduce it to the world, before it begins an extended marketing campaign to let the world know that it is about to change things. I'm serious. Things are about to get really good for my subscribers. Why did they come to me?
1. Because I tell it like it is.
2. I won't back a company whose only purpose is to pump and dump.
3. I stick with a stock and I talk about it until we make money or I admit that I was wrong.
4. They like my style and obviously so do you.
So in appreciation of the company's faith in my service, I'm researching and researching and researching. I will bring you all the information I can. Next week, I expect to release the symbol to you. You will be the first to hear of it. And then I want you to consider investing. Not play it for a pop. Invest.
This one is going to be bigger than LUXR. Much bigger.
Considering so many promoters are on this thing today, this thing is performing terribly. At last count, these are the ones I saw:
firstmicrocapreport (Friday)
pennystocksfordummies
primetimestocks
actualgains
movingpennies
pennystockdaytrades